Remodelling of resistance arteries in genetically hypertensive rats by treatment with valsartan, an angiotensin II receptor antagonist

Clinical and Experimental Pharmacology and Physiology

Volumn 23, Issue 6-7, 1996, Pages 576-578

  Ledingham, Janet M ^a   Laverty, R ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

angiotensin converting enzyme inhibitors; AT1 receptor antagonist; blood pressure; cardiac hypertrophy; genetic hypertension; genetically hypertensive inbred rat strain; morphology; remodelling; resistance arteries

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; VALSARTAN;

ANIMAL MODEL; ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; HEART HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART VENTRICLE REMODELING; HYPERTENSION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MUSCLE HYPERTROPHY; NONHUMAN; RAT; RECEPTOR BLOCKING; RESISTANCE BLOOD VESSEL; VASCULAR SMOOTH MUSCLE;

EID: 0029902670     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1681.1996.tb02784.x     Document Type: Conference Paper

References (15)

1. Ledingham JM, Phelan EL, Cross M, Laverty R, Millar JA. Remodelling of resistance arteries by treatment with enalapril in the New Zealand genetically hypertensive (GH) rat. Clin. Exp. Pharmacol. Physiol. 1994; 21: 235-7.
2. Ledingham JM, Laverty R. Long-term effects of treatment with enalapril on the structure of mesenteric resistance arteries in New Zealand genetically hypertensive rats. Clin. Exp. Pharmacol. Physiol. 1995; 22 (Suppl. 1): S350-2.
3. Timmermans PBMWM, Wong PC, Chiu AT et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol. Rev. 1993; 45: 205-51.
4. 1-receptor subtype. Br. J. Pharmacol. 1993; 110: 761-71.
5. Warman LP, Griffin MA, Ledingham JM, Laverty R. The effects of valsartan on mesenteric resistance vessel structure, heart weight and blood pressure in the NZ GH rat. Proc. Aust. Soc. Clin. Exp. Pharmacol. Toxicol. 1994; 1: 123.
6. Heagerty AM, Aalkjaer C, Bund SJ, Korsgaard N, Mulvany MJ. Small artery structure in hypertension: Dual process of remodelling and growth. Hypertension 1993; 21: 391-7.
7. Phelan EL. The New Zealand strain of rats with genetic hypertension N.Z. Med. J. 1968; 67: 334-44.
8. Simpson FO, Phelan EL, Ledingham JM, Millar JA. Hypertension in the genetically hypertensive (GH) strain. In: Ganten D, de Jong W (eds). Handbook of Hypertension, vol. 16, Experimental and Genetic Models of Hypertension. Elsevier Science BV, Amsterdam. 1994; Ch. 11.
9. Gundersen HJG, Bendtsen TF, Korbo L et al. Some new, simple and efficient stereological methods and their use in pathological research and diagnosis. Acta Pathol. Microbiol. Immunol. Scand. 1988; 96: 379-94.
10. Gundersen HJG, Bagger P, Bendtsen TF et al. The new stereological tools: Disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis. Ada Pathol. Microbiol. Immunol. Scand. 1988; 96: 857-81.
11. Morton JJ, Beattie EC, Griffin SA, MacPherson F, Lyall F, Russo D. Vascular hypertrophy, renin and blood pressure in the young spontaneously hypertensive rat. Clin. Sci. 1990; 79: 523-30.
12. Soltis EE. Alterations in vascular structure and function after short-term losartan treatment in spontaneously hypertensive rats. J. Pharmacol. Exp. Ther. 1993; 266: 642-6.
13. Mizuno K, Tani M, Hashimoto S et al. Effects of losartan, a nonpeptide angiotensin II receptor antagonist, on cardiac hypertrophy and the tissue II content in spontaneously hypertensive rats. Life Sci. 1992; 51: 367-74.
14. Oddie CJ, Dilley RJ, Kanellakis P, Bobik A. Chronic angiotensin II type receptor antagonism in genetic hypertension: Effects on vascular structure and reactivity. J. Hypertens. 1993; 11: 717-24.
15. Laverty R, Ledingham JM. Effect of losartan and felodipine on structure of mesenteric resistance arteries (MRA) in the New Zealand genetically hypertensive rat strain. Proc. Aust. Soc. Clin. Exp. Pharmacol. Toxicol. 1995; 2: 149.